The Department for Health and Social Care has asked NICE to conduct an appraisal of venetoclax with ibrutinib and obinutuzumab for untreated chronic lymphocytic leukaemia. However, the company have advised that they will not be pursuing a licensing application for venetoclax from the European Medicines Authority for this indication at this time. Therefore, NICE has decided to suspend this appraisal on its work programme. As this appraisal has been referred to NICE we will continue to monitor any development and will update interested parties if the situation changes.
 
Status Suspended
Process TAG

Timeline

Key events during the development of the guidance:

Date Update
12 October 2018 Suspended, The Department for Health and Social Care has asked NICE to conduct an appraisal of venetoclax with ibrutinib and obinutuzumab for untreated chronic lymphocytic leukaemia. However, the company have advised that they will not be pursuing a licensing application for venetoclax from the European Medicines Authority for this indication at this time. Therefore, NICE has decided to suspend this appraisal on its work programme. As this appraisal has been referred to NICE we will continue to monitor any development and will update interested parties if the situation changes.
03 August 2017 In progress, In progress

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance